Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma

Tamer Othman; John H. Baird; Stacy Pak; Matthew Mei; Alex F. Herrera; Joshua Mansour; Geoffrey Shouse; Firoozeh Sahebi; Ricardo Spielberger; Ji Lian Cai; Leonardo Farol; James Godfrey; Avyakta Kallam; Tycel Phillips; Leslie Popplewell; Tanya Siddiqi; Stephen Forman; Lihua E. Budde

doi:10.1111/bjh.19521

Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma

Tamer Othman, John H. Baird, Stacy Pak, Matthew Mei, Alex F. Herrera, Joshua Mansour, Geoffrey Shouse, Firoozeh Sahebi, Ricardo Spielberger, Ji Lian Cai, Leonardo Farol, James Godfrey, Avyakta Kallam, Tycel Phillips, Leslie Popplewell, Tanya Siddiqi, Stephen Forman, Lihua E. Budde

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	368-372
Number of pages	5
Journal	British Journal of Haematology
Volume	205
Issue number	1
DOIs	https://doi.org/10.1111/bjh.19521
State	Published - Jul 2024

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.19521

Cite this

Othman, T., Baird, J. H., Pak, S., Mei, M., Herrera, A. F., Mansour, J., Shouse, G., Sahebi, F., Spielberger, R., Cai, J. L., Farol, L., Godfrey, J., Kallam, A., Phillips, T., Popplewell, L., Siddiqi, T., Forman, S., & Budde, L. E. (2024). Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma. British Journal of Haematology, 205(1), 368-372. https://doi.org/10.1111/bjh.19521

Othman, T, Baird, JH, Pak, S, Mei, M, Herrera, AF, Mansour, J, Shouse, G, Sahebi, F, Spielberger, R, Cai, JL, Farol, L, Godfrey, J, Kallam, A, Phillips, T, Popplewell, L, Siddiqi, T, Forman, S & Budde, LE 2024, 'Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma', British Journal of Haematology, vol. 205, no. 1, pp. 368-372. https://doi.org/10.1111/bjh.19521

@article{de50e75e37ce4bf680c2587c0895e638,

title = "Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma",

author = "Tamer Othman and Baird, {John H.} and Stacy Pak and Matthew Mei and Herrera, {Alex F.} and Joshua Mansour and Geoffrey Shouse and Firoozeh Sahebi and Ricardo Spielberger and Cai, {Ji Lian} and Leonardo Farol and James Godfrey and Avyakta Kallam and Tycel Phillips and Leslie Popplewell and Tanya Siddiqi and Stephen Forman and Budde, {Lihua E.}",

year = "2024",

month = jul,

doi = "10.1111/bjh.19521",

language = "English (US)",

volume = "205",

pages = "368--372",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma

AU - Othman, Tamer

AU - Baird, John H.

AU - Pak, Stacy

AU - Mei, Matthew

AU - Herrera, Alex F.

AU - Mansour, Joshua

AU - Shouse, Geoffrey

AU - Sahebi, Firoozeh

AU - Spielberger, Ricardo

AU - Cai, Ji Lian

AU - Farol, Leonardo

AU - Godfrey, James

AU - Kallam, Avyakta

AU - Phillips, Tycel

AU - Popplewell, Leslie

AU - Siddiqi, Tanya

AU - Forman, Stephen

AU - Budde, Lihua E.

PY - 2024/7

Y1 - 2024/7

UR - http://www.scopus.com/inward/record.url?scp=85194476343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85194476343&partnerID=8YFLogxK

U2 - 10.1111/bjh.19521

DO - 10.1111/bjh.19521

M3 - Letter

C2 - 38797530

AN - SCOPUS:85194476343

SN - 0007-1048

VL - 205

SP - 368

EP - 372

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 1

ER -

Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this